JP2015503512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503512A5 JP2015503512A5 JP2014549075A JP2014549075A JP2015503512A5 JP 2015503512 A5 JP2015503512 A5 JP 2015503512A5 JP 2014549075 A JP2014549075 A JP 2014549075A JP 2014549075 A JP2014549075 A JP 2014549075A JP 2015503512 A5 JP2015503512 A5 JP 2015503512A5
- Authority
- JP
- Japan
- Prior art keywords
- patent document
- growth
- releasing
- pat
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100007206 GHRH Human genes 0.000 description 10
- 101710044881 GHRH Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000002194 synthesizing Effects 0.000 description 8
- 210000004027 cells Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000003488 releasing hormone Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000006011 modification reaction Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 206010012601 Diabetes mellitus Diseases 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- QYPPJABKJHAVHS-UHFFFAOYSA-N agmatine Chemical group NCCCCNC(N)=N QYPPJABKJHAVHS-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 210000001015 Abdomen Anatomy 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 102100011487 CRHR1 Human genes 0.000 description 1
- 101710042290 CRHR1 Proteins 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 240000002275 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 101700062901 DPP Proteins 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N Dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
- QBEPNUQJQWDYKU-BMGKTWPMSA-N Egrifta Chemical compound C([C@H](NC(=O)C/C=C/CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O)C1=CC=C(O)C=C1 QBEPNUQJQWDYKU-BMGKTWPMSA-N 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 210000002660 Insulin-Secreting Cells Anatomy 0.000 description 1
- 102000004218 Insulin-like growth factor I Human genes 0.000 description 1
- 108090000723 Insulin-like growth factor I Proteins 0.000 description 1
- 210000004153 Islets of Langerhans Anatomy 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-2-aminohexanoic acid zwitterion Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N Octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 241001272996 Polyphylla fullo Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010053803 Sermorelin Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003667 anti-reflective Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- CNYFJCCVJNARLE-UHFFFAOYSA-L calcium;2-sulfanylacetic acid;2-sulfidoacetate Chemical compound [Ca+2].[O-]C(=O)CS.[O-]C(=O)CS CNYFJCCVJNARLE-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003293 cardioprotective Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940119350 dehydroepiandrosterone Drugs 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002107 myocardial Effects 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 229960001874 tesamorelin Drugs 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
Description
本発明は、その好ましい実施形態に関して説明されているが、前記実施形態は、本発明者らが現在知っているベストモードを構築する。種々の変化および修飾が、本願明細書に添付の特許請求の範囲において説明される本発明の範囲から逸脱することなくなされ得ることは、当業者に明らかであろう。例えば、ペプチド鎖における修飾、特に前記ペプチドのカルボキシル末端から始まる欠失および29位付近への伸長は、前記ペプチドの生物学的活性の全部または非常に実質的な部分を保持するペプチドまたはぺプチドのフラグメントを生成するために、現在までに公知の実験的実務に基づいてなされ得る。このようなペプチドは、本発明の範囲内であると見なされる。さらに、本発明の範囲から逸脱することなく、特許請求されたポリペプチドの活性の少なくとも実質的な部分を有する他の類似体を生成するために、付加が、いずれかの末端または両末端になされてもよく、および/または、一般的に同等の残基は、ペプチド化学の全分野において周知のように、自然に発生する残基に置換され得る。さらに、修飾は、今日のこの分野の情勢に基づいて、C末端における好ましい−−NH2基になされてもよい。例えば、前記C末端でのアミノ酸残基のカルボキシル部分は、基−−COOR、−−CRO、−−CONHNHR、−−CON(R)(R’)、または−−CH2−ORであり得る。RおよびR’は、低級アルキル、フルオロ低級アルキル、または水素である。本発明から逸脱することなく、このような修飾については、同等の合成ペプチドをもたらす(Rivier 米国特許第5262519号明細書)。
この出願の発明に関連する先行技術文献情報としては、以下のものがある(国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む)。
(先行技術文献)
(特許文献)
(特許文献1) 中国特許出願公開第1328570号明細書
(特許文献2) 中国特許出願公開第1871020号明細書
(特許文献3) 欧州特許出願公開第0413839号明細書
(特許文献4) 米国特許第4,622,312号明細書
(特許文献5) 米国特許第4,649,131号明細書
(特許文献6) 米国特許第4,689,318号明細書
(特許文献7) 米国特許第4,784,987号明細書
(特許文献8) 米国特許第4,914,189号明細書
(特許文献9) 米国特許第5,262,519号明細書
(特許文献10) 米国特許第5,792,747号明細書
(特許文献11) 米国特許第5,846,936号明細書
(特許文献12) 米国特許第7,241,744号明細書
(特許文献13) 米国特許第7,268,113号明細書
(特許文献14) 米国特許第7,928,063号明細書
(特許文献15) 米国特許出願公開第2005/0261201号明細書
(特許文献16) 米国特許出願公開第2007/0042950号明細書
(特許文献17) 米国特許出願公開第2009/0023646号明細書
(特許文献18) 米国特許出願公開第2010/0092539号明細書
(特許文献19) 国際公開第03/037928号
(特許文献20) 国際公開第90/12810号
(特許文献21) 国際公開第94/11396号
(特許文献22) 国際公開第94/11397号
(特許文献23) 国際公開第96/22782号
(特許文献24) 国際公開第97/42223号
(特許文献25) 国際公開第2009/009727号
(特許文献26) 国際公開第2011/034976号
(特許文献27) 国際公開第2011/153491号
(非特許文献)
(非特許文献1) European Search Report for 12860298.4 dated September 28,2015
(非特許文献2) Armann et al.,"Quantification of basal and stimulated ROS levels as predictors of islet potency and function,"Am J Transplant,(2007),7:38−47.
(非特許文献3) Bajusz,et al.in Peptides,1982,Blaha and Melon,Eds.de Gruyter,Berlin−N.Y.,1983,pp.643−647.
(非特許文献4) Bonner−Weir,"In vitro cultivation of human islets from expanded ductal tissue,"Proc Natl Acad Sci USA,(July 5,2000),97(14):7999−8004.
(非特許文献5) Cai,et al.,"Synthesis of new potent agonistic analogs of growth hormone−releasing hormone(GHRH)and evaluation of their endocrine and cardiac activities,"Peptides(February 2014),52:104−112.Epub: December 25,2013.
(非特許文献6) Campbell,et al.,"GRF analogs and fragments: Correlation between receptor binding,activity and structure,"Peptides(May/June 1991),12(3):569−574.
(非特許文献7) Campbell,et al.,"Rational Design,Synthesis,and Biological Evaluation of Novel Growth Hormone Releasing Factor Analogues,"Biopolymers(Peptide Science),(1995)Vol.37:67−88.
(非特許文献8) Corpas,et al.,"Growth Hormone (GH)−Releasing Hormone−(1−29) Twice Daily Reverses the Decreased GH and Insulin−Like Growth Factor−I Levels in Old Men,"J.Clin.Endacrin.Metabal.(1992),75,530−535.
(非特許文献9) Dor et al.,"Adult pancreatic B−cells are formed by self−duplication rather than stem−cell differentiation,"Nature,(May 6,2004),429:41−44.
(非特許文献10) Falutz,et al.,"Effects of Tesamorelin,a Growth Hormone−Releasing Factor,in HIV_Infected Patients with Abdominal Fat Accumulation: A Randomized Placebo−Controlled Trial With a Safety Extension,"Acquir Immune Defic Syndr.(2010),53: 311−322.
(非特許文献12) Felix,et al.,"Synthesis,biological activity and conformational analysis of cyclic GRF analogs,"Int.J.Peptide Protein Res.(December 1988),32(6): 441−454.
(非特許文献13) Ferninandi,et al.,"Non−Clinical Pharmacology and Safety Evaluation ofTH9507,a Human Growth Hormone−Releasing Factor Analogue,"Basic & Clin Pharmacol Toxicol.(2007),100: 49−58.
(非特許文献14) Fiaschi−Taesch et al.,"Hepatocyte Growth Factor Enhances Engraftment and Function of Nonhuman Primate Islets,"Diabetes,(October 2008),57:2745−2754.
(非特許文献15) Frohman,et al.,"Dipeptidylpeptidase IV and Trypsin−like Enzymatic Degradation of Human Growth Hormone−releasing Hormone in Plasma,"J.Clin.Invest.(1989),83,1533−1540.
(非特許文献16) Granata et al.,"Obestatin promotes survival of pancreatic beta−cells and human islets and induces expression of genes involved in the regulation of beta−cell mass and function,"Diabetes,(April 2008),57:967−979.
(非特許文献17) Granata et al.,"Growth hormone−releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia−reperfusion injury in rat heart,"Cardiovasc Res,(2009),83 :303−312.
(非特許文献18) Guarcello et al.,"Growth hormone releasing hormone receptors on thymocytes and splenocytes from rats,"Cell Immunol,(1991),136:291−902.
(非特許文献19) Havt et al.,"The expression of the pituitary growth hormone−releasing hormone receptor and its splice variants in normal and neoplastic human tissues,"Proc Natl Acad Sci USA(November 29,2005),102(48):17424−17429.
(非特許文献20) Houssay,"[Role of the hypophysis in carbohydrate metabolism and diabetes],"Folia Endoctrinol Mens Incretologia Incretoterapia,(1950) 3(2):127−136.
(非特許文献21) Huising et al.,"CRFRI is expressed on pancreatic B cells,promotes B cell proliferation,and potentiates insulin secretion in a glucose−dependent manner,"Proc Natl Acad Sci USA,(January 12,2010),107(2): 912−917.
(非特許文献22) Izdebski,et al.,"Synthesis and biological evaluation of superactive agonists of growth hormone releasing hormone,"Proc Natl Acad Sci USA,(May 1995),92:4872−4876.
(非特許文献23) Jabs et al.,"Reduced insulin secretion and content in VEGF−a deficient mouse pancreatic islets,"Exp Clin Endoctrinol Diabetes(2008),116 Suppl.1 :S45−49.
(非特許文献24) Kanashiro−Takeuchi et al.,"Cardioprotective effects of growth hormone−releasing hormone agonist after myocardial infarction,"Proc Natl Acad Sci USA,(February 9,2010),107(6):2604−2609.
(非特許文献25) Khorram et al.,"Effects of[Norleucine27]Growth Hormone−Releasing Hormone(GHRH)(1−29)−NH2 Administration on the Immune System of Aging Men and Women,"J Clin Endocrinol Metab,(1997),82(11):3590−3596.
(非特許文献26) Kirk,et al.,"Treatment with GHRH(1−29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity,"Clinical Endocrinol.(October 1994)41(4):487−493.
(非特許文献27) Kovacs,et al.,"An evaluation of intravenous,subcutaneous,and in vitro activity of new agmatine analogs of growth−hormone releasing hormone hGH−RW(1−29)NH2,"Life Science,(1988),42(1): 27−35.
(非特許文献28) Lehmann et al.,"Has time come for new goals in human islet transplantation?,"Am J Transplant,(2008),8: 1096−1100.
(非特許文献29) Letsch et al.,"Growth hormone−releasing hormone(GHRH)antagonists inhibit the proliferation of androgen−dependent and −independent prostate cancers,"Proc Natl Adac Sci USA,(February 4,2003),100(3):1250−1255.
(非特許文献30) Ling et al.,"Isolation,primary structure,and synthesis of human hypothalamic somatocrini: growth hormone−releasing factor,"Proc Natl Acad Sci USA,(1984),81 :4302−4306.
(非特許文献31) Merrifield,"Solid Phase Peptide Synthesis.I.The Synthesis of a Tetrapeptide,"J.Am.Chem.Soc.,(1963),85:2149.
(非特許文献32) Muranishi,et al.,"Lipophilic Peptides: Synthesis of Lauroyl Thyrotropin−Releasing Hormone and Its Biological Activity,"Pharm.Res.(May 1991),8(5)649−652.
(非特許文献33) Nielsen et al.,"Beta cell proliferation and growth factors,"J.Mol.Med.(1999),77:62−66.
(非特許文献34) Rekasi et al.,"Isolation and sequencing of cDNAs for splice variants of growth hormone releasing hormone receptors from human cancers,"Proc Natl Acad Sci USA,(September 12,2000),97(19):10561−10566.
(非特許文献35) Ross,et al.,"Treatment of Growth−Hormone Deficiency with Growth−Hormone−Releasing Hormone,"Lancet 1(January 3,1987),8523:5−8.
(非特許文献36) Schally et al.,"Agonistic Analogs of Growth Hormone−Releasing Hormone: Endocrine and Growth Studies,"Growth Hormone Secretagogues in Clinical Practice (1998),eds.Bercu and Walker,(Marcel Dekker,Inc.New York),131−143.
(非特許文献37) Shapiro et al.,"International trial of the Edmonton protocol for islet transplantation,"N Engl J Med,(2006),355:1318−1330.
(非特許文献38) Takano et al.,"Human growth hormone−releasing hormone(hGH−RH; hGRF)treatment of four patients with GH deficiency,"Endocrinol.Japan(1988)35(5); 775−781.
(非特許文献39) Thorner,et al.,"Acceleration of Growth in Two Children Treated with Human Growth Hormone−Releasing Factor,"N.Engl.J.Med.(January 3,1985),312(1):4−9.
(非特許文献40) Vance,"Growth−Hormone−Releasing Hormone,"Clin Chem,(1990),36:415−420.
(非特許文献41) Vance,"Growth hormone for the elderly?,"N.Eng.J.Med(1990),323(1):52−54.
(非特許文献42) Vasavada et al.,"Growth factors and beta cell replication,"Int J.Biochem Cell Biol,Epub 31,(August 2005),38(5−6):931−950.
(非特許文献43) Witkowska,et al.,"Tryptic Hydrolysis of hGH−RH(1−29)−NH2 Analogues Containing Lys or Orn in Positions 12 and 21,"J.Peptide Sci.7:166−172(2001).
(非特許文献44) Zarandi,et al.,"Synthesis and in vitro and in vivo activity of analogs of growth hormone releasing hormone(GH−RH)with C−terminal agmatine,"Int.J.Peptide Protein Res.(December 1990),36(6):499−505.
(非特許文献45) Zarandi,et al.,"Potent agonists of growth hormone−releasing hormone,"Int.J.Peptide Protein Res.39,1992,211−217.
(非特許文献46) Ziegler et al.,"Dehydroepiandrosterone induces a neuroendocrine phenotype in nerve growth factor−stimulated chromaffin pheochromocytoma PC12 cells,"Endocrinology,(2008),149:320−328.
(非特許文献47) Ziegler et al.,"Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: Antiproliferative effects of peptide analogues,"Proc Natl Acad Sci USA,(September 15,2009),106(37): 15879−15884.
(非特許文献48) International Search Report for PCT/US2012/067690 dated March 28,2013.
この出願の発明に関連する先行技術文献情報としては、以下のものがある(国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む)。
(先行技術文献)
(特許文献)
(特許文献1) 中国特許出願公開第1328570号明細書
(特許文献2) 中国特許出願公開第1871020号明細書
(特許文献3) 欧州特許出願公開第0413839号明細書
(特許文献4) 米国特許第4,622,312号明細書
(特許文献5) 米国特許第4,649,131号明細書
(特許文献6) 米国特許第4,689,318号明細書
(特許文献7) 米国特許第4,784,987号明細書
(特許文献8) 米国特許第4,914,189号明細書
(特許文献9) 米国特許第5,262,519号明細書
(特許文献10) 米国特許第5,792,747号明細書
(特許文献11) 米国特許第5,846,936号明細書
(特許文献12) 米国特許第7,241,744号明細書
(特許文献13) 米国特許第7,268,113号明細書
(特許文献14) 米国特許第7,928,063号明細書
(特許文献15) 米国特許出願公開第2005/0261201号明細書
(特許文献16) 米国特許出願公開第2007/0042950号明細書
(特許文献17) 米国特許出願公開第2009/0023646号明細書
(特許文献18) 米国特許出願公開第2010/0092539号明細書
(特許文献19) 国際公開第03/037928号
(特許文献20) 国際公開第90/12810号
(特許文献21) 国際公開第94/11396号
(特許文献22) 国際公開第94/11397号
(特許文献23) 国際公開第96/22782号
(特許文献24) 国際公開第97/42223号
(特許文献25) 国際公開第2009/009727号
(特許文献26) 国際公開第2011/034976号
(特許文献27) 国際公開第2011/153491号
(非特許文献)
(非特許文献1) European Search Report for 12860298.4 dated September 28,2015
(非特許文献2) Armann et al.,"Quantification of basal and stimulated ROS levels as predictors of islet potency and function,"Am J Transplant,(2007),7:38−47.
(非特許文献3) Bajusz,et al.in Peptides,1982,Blaha and Melon,Eds.de Gruyter,Berlin−N.Y.,1983,pp.643−647.
(非特許文献4) Bonner−Weir,"In vitro cultivation of human islets from expanded ductal tissue,"Proc Natl Acad Sci USA,(July 5,2000),97(14):7999−8004.
(非特許文献5) Cai,et al.,"Synthesis of new potent agonistic analogs of growth hormone−releasing hormone(GHRH)and evaluation of their endocrine and cardiac activities,"Peptides(February 2014),52:104−112.Epub: December 25,2013.
(非特許文献6) Campbell,et al.,"GRF analogs and fragments: Correlation between receptor binding,activity and structure,"Peptides(May/June 1991),12(3):569−574.
(非特許文献7) Campbell,et al.,"Rational Design,Synthesis,and Biological Evaluation of Novel Growth Hormone Releasing Factor Analogues,"Biopolymers(Peptide Science),(1995)Vol.37:67−88.
(非特許文献8) Corpas,et al.,"Growth Hormone (GH)−Releasing Hormone−(1−29) Twice Daily Reverses the Decreased GH and Insulin−Like Growth Factor−I Levels in Old Men,"J.Clin.Endacrin.Metabal.(1992),75,530−535.
(非特許文献9) Dor et al.,"Adult pancreatic B−cells are formed by self−duplication rather than stem−cell differentiation,"Nature,(May 6,2004),429:41−44.
(非特許文献10) Falutz,et al.,"Effects of Tesamorelin,a Growth Hormone−Releasing Factor,in HIV_Infected Patients with Abdominal Fat Accumulation: A Randomized Placebo−Controlled Trial With a Safety Extension,"Acquir Immune Defic Syndr.(2010),53: 311−322.
(非特許文献12) Felix,et al.,"Synthesis,biological activity and conformational analysis of cyclic GRF analogs,"Int.J.Peptide Protein Res.(December 1988),32(6): 441−454.
(非特許文献13) Ferninandi,et al.,"Non−Clinical Pharmacology and Safety Evaluation ofTH9507,a Human Growth Hormone−Releasing Factor Analogue,"Basic & Clin Pharmacol Toxicol.(2007),100: 49−58.
(非特許文献14) Fiaschi−Taesch et al.,"Hepatocyte Growth Factor Enhances Engraftment and Function of Nonhuman Primate Islets,"Diabetes,(October 2008),57:2745−2754.
(非特許文献15) Frohman,et al.,"Dipeptidylpeptidase IV and Trypsin−like Enzymatic Degradation of Human Growth Hormone−releasing Hormone in Plasma,"J.Clin.Invest.(1989),83,1533−1540.
(非特許文献16) Granata et al.,"Obestatin promotes survival of pancreatic beta−cells and human islets and induces expression of genes involved in the regulation of beta−cell mass and function,"Diabetes,(April 2008),57:967−979.
(非特許文献17) Granata et al.,"Growth hormone−releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia−reperfusion injury in rat heart,"Cardiovasc Res,(2009),83 :303−312.
(非特許文献18) Guarcello et al.,"Growth hormone releasing hormone receptors on thymocytes and splenocytes from rats,"Cell Immunol,(1991),136:291−902.
(非特許文献19) Havt et al.,"The expression of the pituitary growth hormone−releasing hormone receptor and its splice variants in normal and neoplastic human tissues,"Proc Natl Acad Sci USA(November 29,2005),102(48):17424−17429.
(非特許文献20) Houssay,"[Role of the hypophysis in carbohydrate metabolism and diabetes],"Folia Endoctrinol Mens Incretologia Incretoterapia,(1950) 3(2):127−136.
(非特許文献21) Huising et al.,"CRFRI is expressed on pancreatic B cells,promotes B cell proliferation,and potentiates insulin secretion in a glucose−dependent manner,"Proc Natl Acad Sci USA,(January 12,2010),107(2): 912−917.
(非特許文献22) Izdebski,et al.,"Synthesis and biological evaluation of superactive agonists of growth hormone releasing hormone,"Proc Natl Acad Sci USA,(May 1995),92:4872−4876.
(非特許文献23) Jabs et al.,"Reduced insulin secretion and content in VEGF−a deficient mouse pancreatic islets,"Exp Clin Endoctrinol Diabetes(2008),116 Suppl.1 :S45−49.
(非特許文献24) Kanashiro−Takeuchi et al.,"Cardioprotective effects of growth hormone−releasing hormone agonist after myocardial infarction,"Proc Natl Acad Sci USA,(February 9,2010),107(6):2604−2609.
(非特許文献25) Khorram et al.,"Effects of[Norleucine27]Growth Hormone−Releasing Hormone(GHRH)(1−29)−NH2 Administration on the Immune System of Aging Men and Women,"J Clin Endocrinol Metab,(1997),82(11):3590−3596.
(非特許文献26) Kirk,et al.,"Treatment with GHRH(1−29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity,"Clinical Endocrinol.(October 1994)41(4):487−493.
(非特許文献27) Kovacs,et al.,"An evaluation of intravenous,subcutaneous,and in vitro activity of new agmatine analogs of growth−hormone releasing hormone hGH−RW(1−29)NH2,"Life Science,(1988),42(1): 27−35.
(非特許文献28) Lehmann et al.,"Has time come for new goals in human islet transplantation?,"Am J Transplant,(2008),8: 1096−1100.
(非特許文献29) Letsch et al.,"Growth hormone−releasing hormone(GHRH)antagonists inhibit the proliferation of androgen−dependent and −independent prostate cancers,"Proc Natl Adac Sci USA,(February 4,2003),100(3):1250−1255.
(非特許文献30) Ling et al.,"Isolation,primary structure,and synthesis of human hypothalamic somatocrini: growth hormone−releasing factor,"Proc Natl Acad Sci USA,(1984),81 :4302−4306.
(非特許文献31) Merrifield,"Solid Phase Peptide Synthesis.I.The Synthesis of a Tetrapeptide,"J.Am.Chem.Soc.,(1963),85:2149.
(非特許文献32) Muranishi,et al.,"Lipophilic Peptides: Synthesis of Lauroyl Thyrotropin−Releasing Hormone and Its Biological Activity,"Pharm.Res.(May 1991),8(5)649−652.
(非特許文献33) Nielsen et al.,"Beta cell proliferation and growth factors,"J.Mol.Med.(1999),77:62−66.
(非特許文献34) Rekasi et al.,"Isolation and sequencing of cDNAs for splice variants of growth hormone releasing hormone receptors from human cancers,"Proc Natl Acad Sci USA,(September 12,2000),97(19):10561−10566.
(非特許文献35) Ross,et al.,"Treatment of Growth−Hormone Deficiency with Growth−Hormone−Releasing Hormone,"Lancet 1(January 3,1987),8523:5−8.
(非特許文献36) Schally et al.,"Agonistic Analogs of Growth Hormone−Releasing Hormone: Endocrine and Growth Studies,"Growth Hormone Secretagogues in Clinical Practice (1998),eds.Bercu and Walker,(Marcel Dekker,Inc.New York),131−143.
(非特許文献37) Shapiro et al.,"International trial of the Edmonton protocol for islet transplantation,"N Engl J Med,(2006),355:1318−1330.
(非特許文献38) Takano et al.,"Human growth hormone−releasing hormone(hGH−RH; hGRF)treatment of four patients with GH deficiency,"Endocrinol.Japan(1988)35(5); 775−781.
(非特許文献39) Thorner,et al.,"Acceleration of Growth in Two Children Treated with Human Growth Hormone−Releasing Factor,"N.Engl.J.Med.(January 3,1985),312(1):4−9.
(非特許文献40) Vance,"Growth−Hormone−Releasing Hormone,"Clin Chem,(1990),36:415−420.
(非特許文献41) Vance,"Growth hormone for the elderly?,"N.Eng.J.Med(1990),323(1):52−54.
(非特許文献42) Vasavada et al.,"Growth factors and beta cell replication,"Int J.Biochem Cell Biol,Epub 31,(August 2005),38(5−6):931−950.
(非特許文献43) Witkowska,et al.,"Tryptic Hydrolysis of hGH−RH(1−29)−NH2 Analogues Containing Lys or Orn in Positions 12 and 21,"J.Peptide Sci.7:166−172(2001).
(非特許文献44) Zarandi,et al.,"Synthesis and in vitro and in vivo activity of analogs of growth hormone releasing hormone(GH−RH)with C−terminal agmatine,"Int.J.Peptide Protein Res.(December 1990),36(6):499−505.
(非特許文献45) Zarandi,et al.,"Potent agonists of growth hormone−releasing hormone,"Int.J.Peptide Protein Res.39,1992,211−217.
(非特許文献46) Ziegler et al.,"Dehydroepiandrosterone induces a neuroendocrine phenotype in nerve growth factor−stimulated chromaffin pheochromocytoma PC12 cells,"Endocrinology,(2008),149:320−328.
(非特許文献47) Ziegler et al.,"Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: Antiproliferative effects of peptide analogues,"Proc Natl Acad Sci USA,(September 15,2009),106(37): 15879−15884.
(非特許文献48) International Search Report for PCT/US2012/067690 dated March 28,2013.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/332,624 US9079974B2 (en) | 2011-12-21 | 2011-12-21 | GH-RH analogs with potent agonistic effects |
US13/332,624 | 2011-12-21 | ||
PCT/US2012/067690 WO2013095903A1 (en) | 2011-12-21 | 2012-12-04 | Novel gh-rh analogs with potent agonistic effects |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015503512A JP2015503512A (ja) | 2015-02-02 |
JP2015503512A5 true JP2015503512A5 (ja) | 2016-01-28 |
JP6375089B2 JP6375089B2 (ja) | 2018-08-15 |
Family
ID=48669348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014549075A Expired - Fee Related JP6375089B2 (ja) | 2011-12-21 | 2012-12-04 | 強力なアゴニスト作用を有する新規なgh−rh類似体 |
Country Status (10)
Country | Link |
---|---|
US (2) | US9079974B2 (ja) |
EP (1) | EP2794647B1 (ja) |
JP (1) | JP6375089B2 (ja) |
KR (1) | KR102117216B1 (ja) |
CN (1) | CN104520314B (ja) |
AU (1) | AU2012355743B2 (ja) |
CA (1) | CA2859675C (ja) |
IL (1) | IL233186B (ja) |
MX (1) | MX353869B (ja) |
WO (1) | WO2013095903A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9079974B2 (en) * | 2011-12-21 | 2015-07-14 | The University Of Miami | GH-RH analogs with potent agonistic effects |
WO2014100816A2 (en) * | 2012-12-21 | 2014-06-26 | University Of Miami | Ghrh agonists for islet cell transplantation and function and the treatment of diabetes |
US9855312B2 (en) * | 2012-12-21 | 2018-01-02 | University Of Miami | GHRH agonists for the treatment of ischemic disorders |
FR3020810B1 (fr) * | 2014-05-06 | 2016-05-06 | Servier Lab | Nouveau sel de l'ivabradine et son procede de preparation. |
PT3445778T (pt) | 2016-04-19 | 2020-10-15 | Griffon Pharmaceuticals Int Sa C/O Biopole Sa | Péptidos bioativos peguilados e suas utilizações |
CN107320718B (zh) * | 2017-05-23 | 2020-12-11 | 余红 | 促生长激素释放激素激动剂在制备抗血管钙化药物中的应用 |
CN111407884B (zh) * | 2019-06-24 | 2021-12-07 | 浙江大学 | 促生长激素释放激素激动剂ghrh-a在制备抗衰老药物中的用途 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4622312A (en) | 1984-09-24 | 1986-11-11 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
US4649131A (en) | 1984-09-24 | 1987-03-10 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
US4689318A (en) | 1985-08-29 | 1987-08-25 | The Salk Institute For Biological Studies | GRF analogs |
US4784987A (en) | 1987-01-13 | 1988-11-15 | The Salk Institute For Biological Studies | GRF analogs VI |
US4914189A (en) | 1987-02-05 | 1990-04-03 | The Adminstrators Of The Tulane Educational Fund | Synthetic GHRH analogs |
US5098995A (en) * | 1987-05-22 | 1992-03-24 | The Salk Institute For Biological Studies | GRF Analogs VIIA |
US5756458A (en) * | 1989-06-16 | 1998-05-26 | Pharmacia & Upjohn Company | Stabilized potent GRF analogs |
EP0413839A1 (en) | 1989-08-22 | 1991-02-27 | The Administrators of The Tulane Educational Fund | GHRH analogs |
WO1992018531A1 (en) | 1991-04-09 | 1992-10-29 | F. Hoffmann-La Roche Ag | Growth hormone releasing factor analogs |
US5262519A (en) | 1991-05-15 | 1993-11-16 | The Salk Institute For Biological Studies | GRF analogs XI |
WO1994011397A1 (en) * | 1992-11-13 | 1994-05-26 | The Administrators Of The Tulane Educational Fund | Ghrh agonists |
WO1994011396A1 (en) | 1992-11-13 | 1994-05-26 | The Administrators Of The Tulane Educational Fund | Ghrh agonists |
US5792747A (en) * | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
US6458764B1 (en) | 1995-05-26 | 2002-10-01 | Theratechnologies Inc. | GRF analogs with increased biological potency |
US5942489A (en) * | 1996-05-03 | 1999-08-24 | The Administrators Of The Tulane Educational Fund | HGH-RH(1-29)NH2 analogues having antagonistic activity |
US6057422A (en) * | 1998-11-25 | 2000-05-02 | The Administrators Of The Tulane Educational Fund | Antagonistic analogs of GH-RH inhibiting IGF-I and -II |
BR0206919A (pt) * | 2001-02-02 | 2004-07-06 | Conjuchem Inc | Derivados de fator de liberação de hormÈnio de crescimento de longa duração |
PL195917B1 (pl) * | 2001-10-31 | 2007-11-30 | Inst Farmaceutyczny | Nowe peptydy - analogi ludzkiego hormonu uwalniającego hormon wzrostu |
CA2469310C (en) | 2001-12-11 | 2013-01-29 | Advisys, Inc. | Plasmid mediated supplementation for treating chronically ill subjects |
CN1688696A (zh) | 2002-09-18 | 2005-10-26 | 蒙特利尔大学医疗中心 | Ghrh类似物 |
TW200517400A (en) * | 2003-08-05 | 2005-06-01 | Univ Tulane | Antagonistic analogs of GH-RH (2003) |
JP2007531769A (ja) | 2004-03-30 | 2007-11-08 | サファイア セラピューティクス インコーポレイテッド | 成長ホルモン分泌促進薬を使用したc−反応性蛋白質の低減方法 |
US20090088380A1 (en) | 2007-07-12 | 2009-04-02 | Pierrette Gaudreau | Ghrh analogs and therapeutic uses thereof |
CA2718146C (en) | 2008-03-28 | 2016-09-20 | The University Of Miami | Novel n- and c-terminal substituted antagonistic analogs of gh-rh |
US8227421B2 (en) * | 2009-09-17 | 2012-07-24 | University Of Miami | Fluorinated GHRH antagonists |
US8980249B2 (en) * | 2010-06-03 | 2015-03-17 | University Of Miami | Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets |
US9079974B2 (en) * | 2011-12-21 | 2015-07-14 | The University Of Miami | GH-RH analogs with potent agonistic effects |
US9855312B2 (en) * | 2012-12-21 | 2018-01-02 | University Of Miami | GHRH agonists for the treatment of ischemic disorders |
WO2014100816A2 (en) * | 2012-12-21 | 2014-06-26 | University Of Miami | Ghrh agonists for islet cell transplantation and function and the treatment of diabetes |
-
2011
- 2011-12-21 US US13/332,624 patent/US9079974B2/en active Active - Reinstated
-
2012
- 2012-12-04 EP EP12860298.4A patent/EP2794647B1/en active Active
- 2012-12-04 KR KR1020147020457A patent/KR102117216B1/ko active IP Right Grant
- 2012-12-04 MX MX2014007402A patent/MX353869B/es active IP Right Grant
- 2012-12-04 AU AU2012355743A patent/AU2012355743B2/en active Active
- 2012-12-04 CA CA2859675A patent/CA2859675C/en active Active
- 2012-12-04 CN CN201280070383.9A patent/CN104520314B/zh not_active Expired - Fee Related
- 2012-12-04 JP JP2014549075A patent/JP6375089B2/ja not_active Expired - Fee Related
- 2012-12-04 WO PCT/US2012/067690 patent/WO2013095903A1/en active Application Filing
-
2014
- 2014-06-17 IL IL233186A patent/IL233186B/en active IP Right Grant
-
2015
- 2015-06-11 US US14/736,971 patent/US20150274798A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015503512A5 (ja) | ||
US20220160818A1 (en) | Pharmaceutical compositions | |
EP2490709B1 (en) | Peptidic glp-2 agonists | |
US7888317B2 (en) | Glucagon-like peptide-2 and its therapeutic use | |
US5990077A (en) | Glucagon-like peptide-2 and its therapeutic use | |
US6184201B1 (en) | Intestinotrophic glucagon-like peptide-2 analogs | |
EP1231219B1 (en) | GLucagon-like peptide-2 analogs | |
KR100699422B1 (ko) | 부갑상선 호르몬의 동족체 | |
Rivier et al. | Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat | |
US20070299009A1 (en) | Analogs of parathyroid hormone | |
CN105307672A (zh) | 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂 | |
TW201201829A (en) | Novel peptides and methods for their preparation and use | |
CN104093735A (zh) | 新的胰高血糖素类似物 | |
CN112409460A (zh) | 一类glp-1/胰高血糖素受体双重激动剂及其应用 | |
CN1377371A (zh) | 用于治疗骨质疏松症的甲状旁腺激素类似物 | |
JP6375089B2 (ja) | 強力なアゴニスト作用を有する新規なgh−rh類似体 | |
US20030207809A1 (en) | Methods of enhancing functioning of the large intestine | |
CA2527039A1 (en) | Grf analog compositions and their use | |
Rivier et al. | Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat | |
EP3539551B1 (en) | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | |
JP2002513801A (ja) | Pth2レセプター選択的化合物 | |
Rivier et al. | Design of potent dicyclic (4− 10/5− 8) gonadotropin releasing hormone (GnRH) antagonists | |
Meurer et al. | Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin (9–39) | |
Nishizawa et al. | A potent neuromedin U receptor 2-selective alkylated peptide |